FDA Taking Another Look at Controversial Parkinson’s Drug

Comments (0)

Two years ago, the U.S. Food and Drug Administration reviewed a Parkinson’s drug called Nuplazid. At that time, the lead reviewer issued warnings about the potential risks of the drug. He observed that those who were taking the drug were suffering extreme side effects twice as much as those people who were taking placebos. He also expressed concerns that the potential benefits of the drug may not outweigh the risks of the drug.

Since the drug came on the market, it has grossed about $125 million for the drug company. About 1,000 people have also made reports of adverse events related to the drug. One organization reported that 244 deaths have been linked to Nuplazid.

Recently, an administrator with the FDA told Congressional leaders that the agency was taking another look at the medication. As of now, the reported deaths have not been definitively linked to Nuplazid, but the drug has been labeled as a “suspect” drug. According to the FDA, many of the adverse events have involved elderly patients who have been suffering from Parkinson’s disease for a long time. Also, many of the patients have been diagnosed with other conditions and were taking other drugs in addition to Nuplazid.

Unfortunately, many unsafe prescription drugs make it onto the market, despite all the government regulations designed to protect the public from dangerous prescription drugs. When a dangerous prescription drug does find its way into the market place, and consumers are harmed as a result, the pharmaceutical company can be held liable.

If you have been harmed by a dangerous prescription drug, call the Houston personal injury attorneys at Kennedy Hodges at 855-947-0707. You can also learn more about the firm on our Facebook page.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.